ALVO · Alvotech · Stock research

KYMR

Kymera Therapeutics, Inc.

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing, stretched theme structurally supported on a pullback to the $100 shelf rather than into the catalyst gap.

SYRE

Spyre Therapeutics, Inc.

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026, overdue) and SPY072 RA topline (accelerated to Q3) — are the near-term binaries. Platform de-risked, but distribution flags plus ~1:1 R/R to $100–135 targets argue probe-only into an all-time high.

RVMD

Revolution Medicines, Inc.

Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to $235 (Guggenheim, 2026-07-09). The three-week digestion off the $192.62 high resolved higher on 2026-07-17 (+3.9% to $186.16) — the breakout retest the prior note wanted.

ABT

Abbott Laboratories

De-rating unwind is now largely priced: $82.56 close on 2026-05-11 to $111.25 on 2026-08-14, RSI 72.2, with the 2026-08-11 Google Health/Lingo partnership and Wolfe's 2026-08-13 upgrade to $130 as the newest fuel. Nothing tests the 6.5%–7.5% FY comparable guide against Q2's 4.8% until the ~mid-October Q3 print; ESC Munich on 2026-08-28 is the only dated event inside 30 days.